CUV.AX
EquityCLINUVEL FPO [CUV]
Health Care · Biotechnology
$9.61
+9.61 (+0.00%)
Open
N/A
Day Range
$9.59 - $10.00
52W Range
$9.41 - $14.00
Volume
182K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Inside the Operation That Killed Khamenei
US says 2,000 targets hit as Iran retaliates across Gulf
Tongyu Showcases Integrated Air-Ground-Space Full-Scenario Solutions at MWC 2026, Shaping a Smart and Green Future
Mortgage Rates Rise With Iran Conflict
Periods, old age and communal conflict: Oscar shorts showcase variety
Fair Value Estimate
DDM Value
$2.36
Growth: 7.7% | Req. return: 10%
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ACB | Aurora Cannabis Inc. | $3.71 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.74 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $22.81 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,870.00 | N/A | 5.59% | +0.00% |
| A | Agilent Technologies, Inc. | $116.88 | N/A | 0.85% | +0.00% |
| ABBV | AbbVie Inc. | $234.26 | N/A | 2.84% | +0.00% |
| ABT | Abbott Laboratories | $114.12 | N/A | 2.10% | +0.00% |
About CLINUVEL FPO [CUV]
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
www.clinuvel.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+0.0%
3Y CAGR
+7.7%
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for CUV.AX.